News and Events
SOP Abilene to Open Center for Immunotherapeutic Research
The TTUHSC School of Pharmacy Abilene regional campus has established its first Center
of Excellence, a research center specifically designed to study immunology strategies
to detect and treat human diseases.
In December, the Texas Tech University Board of Regents granted its approval to an
agreement between TTUHSC and the Development Corporation of Abilene that will result
in the Center for Immunotherapeutic Research, which will be located at the SOP's Abilene
The Center's mission includes improving the healthcare of people by developing and
implementing novel immune-based approaches to detect and treat human diseases. It
will feature technologies such as gene expression and protein engineering, hybridoma
generation for monoclonal antibodies, microscopy and flow-cytometry. A Human Immunology
Core will provide support for clinical trials that will focus upon cancer treatment
and immune interventions.
Under terms of the agreement, TTUHSC will spend $4.5 million and the DCOA will spend
$3 million to develop the Center during the next five years.
One of the Center's primary goals of the will be to commercialize research. Dr. Jon
Weidanz, an associate professor at the SOP's Abilene campus, will be director for
the new center. Dr. Weidanz helped bring the SOP its first commercialized research
venture in 2004 when he founded Receptor Logic, a company that researches antibodies
capable of attacking cancerous cells.
The Center for Immunotherapeutic Research is presently working to establish its research
infrastructure and will eventually employ seven faculty members and a total of six
graduate students, post-doctoral fellows and administrative assistants. Dr. Weidanz
said his goal is to hire one of the faculty members sometime this summer and two more